Immunogenicity and safety of co-administered Escherichia coli-produced bivalent HPV-16/18 vaccine and hepatitis E vaccine. | ClinicLens

Human papillomavirus (HPV) and Hepatitis E virus (HEV) infections are major health concerns for women of reproductive age. Administration of HPV and HEV vaccines serves as primary prevention strategies. Our study aimed to demonstrate the immunogenicity and safety of co-administer

Medical Literature · Updated 2026-08-07

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.